Clinical Trial Update: OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial results for OTX-DP in chronic allergic conjunctivitis were completed and the results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• OTX-DP

Snippet

Sponsor: Ocular Therapeutix, Inc. | Conditions: Chronic Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2018-03-29